From January 2019, Sensovann is taking part of the R&D project «KOLS-Praktisk og effektiv oppfølging av Kols-pasienter i kommunene». The project is supported by RFF Oslofjordfondet and has the vision to improve management of chronic diseases at the municipal healthcare services. Sensovann cooperates with Norwegian municipalities in the region, and provides competence to the project on biomarker analysis by electro-optical and electrochemical methods. Our team adapts solutions using experiences accumulated in previous projects so as to meet the worldwide demand towards cost-effective POCs for frequent monitoring of patients with chronic obstructive pulmonary disease.
The technology is expected by our partners to be tested with a small number of patients in the not too distant future, and there are plans for certification of the technology as IVD device.
Direction: Cancer pre-screening
Cancer is one of the leading causes of death globally, and the numbers are associated to limited access to early diagnosis and treatment. There has been an increasing demand to develop new cancer screening tools, suitable for large-population screening and early-stage detection. In this regard, Sensovann is developing the SABIO-POC technology. SABIO-POC detects tumor-signaling molecules in non-invasive body fluids by a photo-activated aptamer assay run in a chip. The test is intended to be convenient and cost-effective, compared to current biomarker testing solutions, which could facilitate utse in large-scale screening programs.
With the necessary funding, we have the vision to validate the assay and to develop a customized reader for on-site analysis of precancer. By future verification of the prototype, in cooperation with key industrial and clinical partners, we envisage bringing the new solution to the market and especially to cancer cases in which early diagnosis is crucial to improved survival, e.g. pancreatic and lung cancer. With effective population screening, healthcare institutions would be able to detect early cancer in larger number of individuals, and giving them the desired early treatment; whilst it is avoided the massive use of CT and/or invasive procedures as the current first measures for searching cancer.